Proneurogen Inc.
Tucson, AZ
- UEI
- CC75K29RDV48
- CAGE
- 71UE6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1970 N Wentworth Rd, Tucson, AZ 85749, USA
- Website
- proneurogen.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Raft Pharmaceuticals LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Bio-Peptides, Inc. | Rockville, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Janusq LLC | Rocky River, OH | — |
| Bolden Therapeutics Inc. | Providence, RI | — |
About the company
Proneurogen Inc. is an early stage biotech company developing novel drug therapeutics to prevent and treat inflammation-induced brain disorders, including pain, cognitive impairment, memory loss, and dementia. Through federal grants, Proneurogen Inc. has provided research and development services focused on novel peptide formulations designed to act on MAS receptors within the neurovascular unit to decrease brain inflammation and reactive oxygen species production while improving cerebral blood flow.
Specific services provided through federal grants have included: development and testing of extended-release formulations of MAS receptor agonist peptides PNA5 and ANG-1-7 using poly(lactic-co-glycolic acid) and other polymers for subcutaneous injection to treat vascular cognitive impairment and Alzheimer’s disease-related dementias; pharmacokinetic, toxicology and other IND-enabling studies of these novel formulations required for FDA approval to advance them to human clinical trials; and scale-up GMP manufacturing of the peptide formulations. Major federal funding agencies have included the National Institutes of Health National Institute on Aging, and National Heart, Lung, and Blood Institute. Partners have included university and industry collaborators.
SBA capabilities narrative
ProNeurogen is clinical stage biopharmaceutical company developing novel peptide based neuroprotective therapeutics. These peptides are targeted towards the treatment and prevention of surgical, disease and injury induced cognitive impairment.
Quick answers
Is Proneurogen Inc. registered in SAM.gov?
Yes. Proneurogen Inc.'s SAM.gov registration is active through July 15, 2027.
What is Proneurogen Inc.'s most recent federal award?
Proneurogen Inc.'s most recent federal grant award is GMP manufacturing and IND enabling studies of extended-release PNA5: a novel therapeutic for treating cognitive… (R43AG085713), from National Institute on Aging (NIH), on September 18, 2023.
On GovTribe
See Proneurogen Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors